Nanotechnology in Life Sciences: From Lab to Production

When: October 17, 2019, 5:30 pm - 8:00 pm
Where: IPSEN, 650 E Kendall St, Cambridge, MA

Nanotechnology offers many exciting possibilities in target-oriented delivery of precision medicines. Life science companies are leveraging nanotechnology to advance delivery for improved efficacy in new therapeutics as well as optimize existing medicines.

PROGRAM SUMMARY: Nanotechnology offers many exciting possibilities in target-oriented delivery of precision medicines. Life science companies are leveraging nanotechnology to advance delivery for improved efficacy in new therapeutics as well as optimize existing medicines. Learn about how industry leaders are adopting this technology into their process and the benefits they are able to achieve by doing so. PRESENTATION ABSTRACTS: Mimi Panagiotou, President/CEO, Delphi Scientific, LLC Nanotechnology promises the development of novel diagnostics and therapeutics with enhanced and targeting abilities and high bioavailability. Therapeutic areas include cancer drugs, nucleic acid therapeutics, ocular drugs, vaccines, contrast agents for MRI, only to mention a few. Although numerous formulations have been successfully tested in the lab and several found their way to market, challenges still exist with respect to product quality, scale up and cost-effective production. Presented here are is an integrated approach to nanomaterials development and production, based on the main factors that influence the desired properties, quality characteristics and cost: (a) chemistry/formulation, (b) hardware (processors), and (c) processes (operational maps). Also presented, are examples from the implementation of this approach. Jeff Atkinson, Head of Process Sciences, Ipsen Biosciences Liposomes are the first drug delivery system using nanotechnology to be commercialized for drug delivery. Discovered in 1965, liposomes were first used as a model for biological membranes, later as ingredients in cosmetics, and finally as a drug delivery system. The first liposomal drug product, liposomal doxorubicin, was approved by the FDA in 1995 and only fourteen more pharmaceutical products using liposomal technology have been approved since. Although there has been significant research on nanoliposomes over the past several decades, their use for delivery of bioactives is still considered to be nascent. The broad applicability and potential advantages the technology offers including reduced toxicity, increased stability, biocompatibility, and ability to target delivery sites make nanoliposomes an attractive nanoformulation strategy. Despite the benefits of nanoliposomes, many challenges in the formulation, testing, and manufacturing remain. This presentation is for scientists and engineers interested in learning about the advantages and challenges of using nanoliposomes as a drug delivery system. WHO SHOULD ATTEND: The target audience is scientist and engineers involved in development of nanotechnology based therapeutics, including: Formulators, analytical chemists, process engineers and equipment manufacturers. SPEAKERS: Mimi Panagiotou, President/CEO, Delphi Scientific, LLC Dr. Panagiotou the President and CEO of Delphi Scientific, LLC, a company that develops pharmaceutical nano-formulations. Additionally, she currently serves as an expert witness in patent challenges in the Pharmaceutical Nanotechnology space. Prior, she was the CTO of the Materials Processing Group, IDEX Corporation. In that position, Dr. Panagiotou was responsible for the overall direction of the technology, new product development and collaborations with the Industry and Academia. Dr. Panagiotou holds a MS and Ph.D. in Mechanical Engineering from Northeastern University. She co-authored over 60 papers for journals and conference proceedings, and is a co-inventor in several patents. Further, she led the development and commercialization effort of an award winning microreaction technology (NANO 50TM International award). Jeff Atkinson, Head of Process Sciences, Ipsen Biosciences Dr. Jeff Atkinson started his career at Southern Research Institute (SR) in 1996 as a researcher in controlled release of pharmaceuticals. While at SR he gained experience in microparticle formulation and process development, clinical manufacturing, and project management. In 2005 SRI spun out the controlled release group to form Brookwood Pharmaceuticals where he continued to develop expertise in the field of controlled release working on multiple delivery platforms such as microparticles, liposomes, and solid lipid nanoparticles. Over the years Jeff worked in various roles including researcher, lead scientist, production supervisor, and project manager. About a year after Brookwood Pharmaceuticals was formed, he left full-time employment to work on a doctorate in chemistry. While in graduate school he consulted for Brookwood Pharmaceuticals, SurModics Pharmaceuticals, and Evonik – Birmingham Labs providing expertise in process development, validation, and clinical manufacturing. After completing his doctorate, Jeff joined Evonik in 2012 as the Director of Parenteral Formulation Development at Evonik – Birmingham Laboratories. In September 2017 Jeff joined Ipsen as the Head of Process Science at the Cambridge, US site. He holds a B.S. in Biochemistry from Brigham Young University and a Ph.D. in Chemistry from the University of Alabama at Birmingham. MEETING MANAGER: Janelle Carretero, NECI

Learn more »

Connect With Us

Blog Facebook LinkedIn Twitter